Semaglutide and NAION: Comprehensive Review of the Eye Safety Signal

Comprehensive review of semaglutide and non-arteritic anterior ischemic optic neuropathy synthesizes all available evidence on this potential GLP-1 drug eye safety concern.

Amini, Abdullah et al.·Acta ophthalmologica·2025·Moderate EvidenceReview
RPEP-09927ReviewModerate Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Review
Evidence
Moderate Evidence
Sample
N=not applicable
Participants
Review covering semaglutide users across specialty clinic, population, and clinical trial data

What This Study Found

Comprehensive review of semaglutide and non-arteritic anterior ischemic optic neuropathy synthesizes all available evidence on this potential GLP-1 drug eye safety concern.

Key Numbers

Review covers the original matched cohort study, subsequent unselected population studies, and a meta-analysis of clinical trials examining the semaglutide-NAION association.

How They Did This

In publication.

Why This Research Matters

Relevant to peptide therapeutics.

The Bigger Picture

Advances peptide evidence.

What This Study Doesn't Tell Us

In publication.

Questions This Raises

  • ?Long-term implications?
  • ?Evidence comparison?
  • ?Next steps?

Trust & Context

Key Stat:
Key finding Comprehensive review of semaglutide and non-arteritic anterior ischemic optic neuropathy synthesizes
Evidence Grade:
Based on design.
Study Age:
Published in 2025.
Original Title:
Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association.
Published In:
Acta ophthalmologica, 103(6), 615-621 (2025)
Database ID:
RPEP-09927

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study

Summarizes existing research on a topic.

What do these levels mean? →

Frequently Asked Questions

What does this mean?

Comprehensive review of semaglutide and non-arteritic anterior ischemic optic neuropathy synthesizes all available evidence on this potential GLP-1 drug eye safety concern.

How reliable?

Consult publication.

Read More on RethinkPeptides

Cite This Study

RPEP-09927·https://rethinkpeptides.com/research/RPEP-09927

APA

Amini, Abdullah; Hamann, Steffen; Larsen, Michael. (2025). Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association.. Acta ophthalmologica, 103(6), 615-621. https://doi.org/10.1111/aos.17473

MLA

Amini, Abdullah, et al. "Semaglutide and non-arteritic anterior ischaemic optic neuropathy: Review and interpretation of reported association.." Acta ophthalmologica, 2025. https://doi.org/10.1111/aos.17473

RethinkPeptides

RethinkPeptides Research Database. "Semaglutide and non-arteritic anterior ischaemic optic neuro..." RPEP-09927. Retrieved from https://rethinkpeptides.com/research/amini-2025-semaglutide-and-nonarteritic-anterior

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.